Pfizer is hoping for earlier use of Elrexfio (elranatamab) in relapsed or refractory multiple myeloma (RRMM) after the drug ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer has reached settlement agreements with Dexcel Pharma, Hikma Pharmaceuticals, and Cipla, delaying generic competition for its blockbuster ATTR-CM drug Vyndamax until 2031. The move preserves ...

Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in ...

April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...

April 29 () - Pfizer said on Wednesday its drug Elrexfio met the main goal in ‌a late-stage trial that tested the blood ...

RNA rewards companies that can integrate biology, data science, manufacturing, and clinical development into a single ...

Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...

Pfizer (PFE) stock is in focus as a trial for the company's Elrexfio multiple myeloma drug hit the main goal with patients on ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.